)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Alzinova
Alzinova (ALZ) investor relations material
Alzinova Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary12 Nov, 2026
Executive summary
ALZ-101’s global Phase IIa ADVANCE study entered operational start-up; first participant enrollment is targeted around the turn of 2026/2027.
A rights issue completed after quarter-end raised approximately SEK 44.0 million before issue costs, supporting trial preparations and related manufacturing and quality work.
Amsterdam UMC diagnostic research found measurable antibodies against toxic amyloid-beta oligomers and lower reactivity in Alzheimer’s patients than age-matched controls.
Financial highlights
Q3 loss after financial items was SEK 4.977 million, versus SEK 6.960 million; 9M loss was SEK 16.451 million, versus SEK 20.375 million.
Q3 operating expenses were SEK 13.759 million versus SEK 12.967 million; R&D costs were SEK 8.752 million versus SEK 6.003 million.
Q3 cash flow was negative SEK 12.565 million versus negative SEK 11.025 million; 9M cash flow was positive SEK 424,000 versus negative SEK 15.010 million.
Cash and cash equivalents were SEK 744,000 at September 30, 2026, versus SEK 485,000 a year earlier.
Outlook and guidance
ADVANCE is planned to enroll approximately 120 participants aged 50–85; study execution and results analysis are scheduled for 2027–2028.
The Phase IIa primary efficacy endpoint is change in cognitive function after 52 weeks, measured using ADCOMS; total follow-up is 92 weeks.
Recruitment preparations continue at seven selected US sites; 20 additional sites are planned across Europe and the UK.
A European clinical trial application via CTIS was planned for November; first US enrollment remains targeted around the turn of 2026/2027.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Alzinova
- Strong clinical progress and new capital support advance diagnostics and Phase II preparations.ALZ
Q2 2026 - ALZ-101 phase 1b milestones reached, rights issue completed, and phase 2 preparations underway.ALZQ3 2024
- Advanced ALZ-101 to Phase II and expanded into diagnostics, supported by a strengthened financial base.ALZQ1 2026
- Advanced ALZ-101, secured new funding, and set sights on Phase II and partnerships in 2026.ALZQ4 2025
- FDA Fast Track for ALZ-101 advances Phase II plans; financing secured for near-term operations.ALZQ3 2025
- A novel Alzheimer's vaccine shows promise for safe, affordable, and accessible treatment.ALZInvesting in Life Science 2025
- Advanced ALZ-101 to Phase II readiness, secured SEK 30.3M, and strengthened financials.ALZQ2 2025
- ALZ-101 showed strong safety, immune response, and cognitive benefit trends in phase 1b.ALZStudy Result
- Alzinova raised SEK 34.4M and advanced ALZ-101, with key phase 1b data expected in Q4 2024.ALZQ2 2024
Next Alzinova earnings date
Q4 202625 Feb, 2027
Alzinova
Next Alzinova earnings date
Q4 202625 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Alzinova AB is a Swedish biotechnology company focused on developing treatments for Alzheimer's disease. The company's lead product is ALZ-101, a vaccine designed to target toxic oligomers of amyloid-beta, which are implicated in the progression of Alzheimer's. ALZ-101 has completed part A of its phase 1b clinical trial and continues to progress through clinical development. Alzinova is also working on ALZ-201, a monoclonal antibody that neutralizes these toxic oligomers, with a humanized version in early clinical trials. The company is headquartered in Mölndal, Sweden, and its shares are listed on the Stockholm Stock Exchange.